Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes) by Stohl, William
BLyS (also commonly known as BAFF) and the closely 
related APRIL are members of the TNF ligand super-
family. Th   ese molecules have enjoyed considerable atten-
tion from a diverse audience, ranging from basic investi-
gators studying B-cell biology to clinical rheu  matologists 
eagerly anticipating (and praying for) new (better) 
medica  tions for their patients with systemic lupus 
erythematosus (SLE).
In general, individual members of the TNF ligand 
superfamily are highly parochial. Th  at is, they routinely 
exist in homotrimeric form and, thereby, exclude other 
TNF ligand superfamily members from their complex 
domains. In sharp contrast, the recent report by Dillon 
and colleagues reminds us that BLyS and APRIL can, and 
do, couple with each other as heterotrimers [1]. By 
extending the previous ﬁ  ndings of Roschke and colleagues 
[2], Dillon and colleagues have convincingly documented 
the in vitro biologic activity of their recombinant BLyS/
APRIL heterotrimers (whose stoichiometry is predomi-
nantly two parts APRIL plus one part BLyS) and the 
ability of soluble fusion proteins expressing either of two 
BLyS receptors (TACI and BCMA, which each also bind 
APRIL), but not the third BLyS receptor (BAFFR, which 
does not bind APRIL), to neutralize the in vitro biologic 
activity of these recombinant heterotrimers.
Th  e clinical interest in the BLyS axis (which includes 
BLyS, APRIL, and the three BLyS receptors) initially 
stemmed from experiments in mice. Th  ese experiments, 
on the one hand, demonstrated causality between BLyS 
over  expression and development of SLE and, on the other 
hand, documented the amelioration of clinical disease in 
SLE mice following either treatment with a BLyS 
antagonist or the genetic elimination of BLyS [3-6]. Th  e 
relevance of these observations in mice to the human 
condition was buttressed by the ﬁ  ndings of BLyS over-
expression in human SLE and the correlation of disease 
activity with circulating BLyS levels in these patients [7,8].
Th   e appeal of BLyS as a therapeutic target has prompted 
substantial time and eﬀ  ort (and money) in the develop-
ment of BLyS antagonists. Th   e two BLyS antagonists that 
are the furthest advanced in clinical development are 
belimumab, an anti-BLyS monoclonal antibody, and 
atacicept, a fusion protein between TACI and the Fc 
portion of IgG. Results from phase II and phase III trials 
have demon  strated modest, but statistically signiﬁ  cant, 
eﬃ     cacy for belimumab in SLE [9,10], and late-stage 
clinical trials with atacicept in SLE are either currently 
underway or will soon begin.
It must be stressed that although belimumab and 
atacicept each binds to and neutralizes BLyS, their res-
pec  tive biologic activities importantly diﬀ  er. Belimumab 
has no APRIL-neutralizing capacity, whereas atacicept is 
fully capable of neutralizing APRIL. Although APRIL-
overexpressing mice, in marked contradistinction to 
BLyS-overexpressing mice, develop only subtle immuno-
logical abnormalities with no serological or clinical 
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© 2010 BioMed Central Ltdautoimmune features [11], APRIL does contribute to 
plasma cell survival [12]. Accordingly, APRIL may 
enhance the longevity of autoantibody-producing plasma 
cells in a SLE host, and its neutralization may therefore 
result in decreased production of autoantibodies. Due to 
the fact that atacicept (TACI-Ig), but not the BLyS-
speciﬁ   c BAFFR-Ig, neutralized the in vitro biologic 
activity of the recombinant BLyS/APRIL heterotrimers of 
Dillon and colleagues [1], atacicept probably neutralizes 
BLyS/APRIL heterotrimers (and APRIL homotrimers) in 
vivo, whereas belimumab may have little-to-no neutraliz-
ing eﬀ  ect on BLyS/APRIL heterotrimers (and no eﬀ  ect 
against APRIL homotrimers).
Whether this probable diﬀ   erential neutralization of 
BLyS/APRIL heterotrimers has any therapeutic ramiﬁ  ca-
tions remains entirely speculative. In principle, the 
biologic activity of BLyS/APRIL heterotrimers in vivo 
may be greater than, less than, or equal to that of BLyS or 
APRIL homotrimers. Accordingly, the net eﬀ  ect of thera-
peutic neutralization of APRIL concomitant with 
neutrali  zation of BLyS might be beneﬁ  cial, harmful, or 
neutral in the context of the ongoing autoimmunity of 
SLE. Of note, the recombinant heterotrimers of Dillon 
and colleagues were considerably less potent in promot-
ing  in vitro human B-cell proliferation than were the 
corresponding BLyS or APRIL homotrimers, raising the 
possibility (but certainly not proving) that the in vivo 
biologic activity of BLyS/APRIL heterotrimers may be 
relatively insigniﬁ  cant in comparison with those of BLyS 
or APRIL homotrimers.
Dillon and colleagues have also documented elevated 
circulating levels of native BLyS/APRIL heterotrimers in 
patients with SLE (but not with rheumatoid arthritis), 
although the precise stoichiometry of these heterotrimers 
in vivo remains unknown. Th   e relative impotence of the 
recombinant BLyS/APRIL heterotrimers coupled to the 
uncertainty surrounding the in vivo stoichiometry of 
BLyS/APRIL heterotrimers highlight our current state of 
ignorance regarding these heterotrimers. We remain in 
the dark with regard to the mechanism and the regulation 
of heterotrimer formation in vivo, the interconversion (if 
any) between homotrimers and heterotrimers, and the 
dysregulation (if any) of such heterotrimers in disease states, 
such as SLE. Nonetheless, the preferential over  expression of 
heterotrimers in SLE, but not in rheumatoid arthritis, raises 
the possibility that such heterotrimers may be playing a 
contributory role in SLE. Development of reagents that can 
speciﬁ  cally neutralize the BLyS (or APRIL) homotrimers but 
not the heterotrimers (or vice versa) will help resolve the 
BLyS/APRIL heterotrimeric enigma.
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